When I worked in medical software, multidrug resistant bacteria were always a concern. But new research has created a class of antibiotics that may make even the most drug-resistant infections history:
[They] focused on a metabolic pathway that is essential for most bacteria but absent in humans, making it an ideal target for antibiotic development. This pathway, called methyl-D-erythritol phosphate (MEP) or non-mevalonate pathway, is responsible for biosynthesis of isoprenoids — molecules required for cell survival in most pathogenic bacteria. The lab targeted the IspH enzyme, an essential enzyme in isoprenoid biosynthesis, as a way to block this pathway and kill the microbes. Given the broad presence of IspH in the bacterial world, this approach may target a wide range of bacteria.
I found it fascinating that the scientists used computer modeling to winnow down millions of possible drug candidates to a few compounds most likely to work, then tested them for real. This reminds me of the CAD/CAM software that has revolutionized manufacturing.
These drugs could be used for a wide variety of stubborn infections, per the original paper in Nature:
they kill clinical isolates of several multidrug-resistant bacteria—including those from the genera Acinetobacter, Pseudomonas, Klebsiella, Enterobacter, Vibrio, Shigella, Salmonella, Yersinia, Mycobacterium and Bacillus—yet are relatively non-toxic to mammalian cells.
This research is in its early stages in mice, but the early results are promising. I can only imagine the many more incredible drugs that may come from using this type of computer modeling for drug discovery.
If you found this post interesting, please share it on Twitter/LinkedIn/email using the buttons below. This helps more people find the blog!